Jasper Therapeutics, Inc.
General ticker "JSPR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $99.0M (TTM average)
Jasper Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -9.0%.
Estimated limits based on current volatility of 11.0%: low 1.52$, high 1.90$
Factors to consider:
- Total employees count: 64 (+42.2%) as of 2024
- Top business risk factors: Operational and conduct risks, Dependence on key products, Regulatory and compliance, Intellectual property risks, Economic downturns and volatility
- Current price 84.0% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [11.65$, 34.89$]
- 2025-12-31 to 2026-12-31 estimated range: [7.02$, 22.54$]
Financial Metrics affecting the JSPR estimates:
- Negative: with PPE of -4.5 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -19.81 <= 0.33
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 77.19 > 63.39
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Negative: negative Industry operating income (median)
Short-term JSPR quotes
Long-term JSPR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $51.20MM | $68.86MM | $76.24MM |
| Operating Income | $-51.20MM | $-68.86MM | $-76.24MM |
| Non-Operating Income | $13.51MM | $4.36MM | $4.97MM |
| R&D Expense | $34.63MM | $51.78MM | $55.82MM |
| Income(Loss) | $-37.69MM | $-64.50MM | $-71.27MM |
| Profit(Loss)* | $-37.69MM | $-64.47MM | $-71.27MM |
| Stockholders Equity | $35.99MM | $78.44MM | $61.67MM |
| Assets | $48.36MM | $94.89MM | $79.90MM |
| Operating Cash Flow | $-45.86MM | $-52.07MM | $-62.60MM |
| Capital expenditure | $0.58MM | $0.27MM | $0.55MM |
| Investing Cash Flow | $-0.58MM | $-0.27MM | $-0.53MM |
| Financing Cash Flow | $0.06MM | $100.97MM | $47.88MM |
| Earnings Per Share** | $-10.33 | $-6.18 | $-4.89 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.